{
  "docId": "019de076-9b15-737c-b05c-8347f7a98ad7",
  "docSlug": "10fcfebbf5ba7c34c2d4aec7e3b05ed6",
  "documentTitle": "Enochian Biosciences | Investor Presentation Deck | 28 slides",
  "authorId": "enochian-biosciences",
  "authorName": "Renovaro Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 28,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide outlines a clinical development plan with specific milestones for 2025 and 2026, focusing on safety and efficacy cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9b15-737c-b05c-8347f7a98ad7/25",
  "deckHref": "/decks/019de076-9b15-737c-b05c-8347f7a98ad7",
  "deckJsonHref": "/decks/019de076-9b15-737c-b05c-8347f7a98ad7.json",
  "deckAnchorHref": "/decks/019de076-9b15-737c-b05c-8347f7a98ad7#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.47
      },
      "kind": "list",
      "text": "Up to 20-25 patients/extending cohort into P2b (assuming responding tumor type)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "645084f8-4b8f-4261-b50c-31dcffb35739",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.33
      },
      "kind": "list",
      "text": "Phase IIa (enrollment starting in late 3Q 2025)– Fixed dose multi-cohort design (one cohort/cancer type)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e29484b-eccf-4777-9656-6fbe91192310",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.1,
        "y": 0.42
      },
      "kind": "list",
      "text": "Assumes high response rate",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75419ea7-c036-4874-9045-357eba70d5c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "list",
      "text": "Phase I (2025) – Safety assessment: Ascending dose ranging cohort of up to 6 patients/dose level",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9a46dcb-cfbc-4661-87b3-4ef6f05a62ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "Phase I/IIa – Open to all solid tumors, focus on Patients with Pancreatic Cancer",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07463870-09c6-462d-b87d-5ad7fb1a7384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Seek Breakthrough and/or RMAT* designation for accelerated development and approval (data to support RMAT available end 2025 / first half of 2026)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f449a47-f845-48eb-8a9c-ff1124db5f69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.76
      },
      "kind": "source-note",
      "text": "* Regenerative Medicine Advanced Therapy (RMAT): accelerated approval pathway for cell and gene therapy qualified product candidates for the Center of Biologics Evaluation and Research of the USA FDA.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3e95baa-0fe0-4346-a957-3e8ecb9af051",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "INITIAL CLINICAL STUDY RENB-DC11-01",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77a37624-3479-4b2c-872f-0ae8912d3806",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 5,
      "beatId": "aa98e201-f5e8-4447-bd2f-449a0dcae7fe",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents RENB-DC11 as a solution, highlighting its efficacy, manufacturing process, and potential for personalized, precision medicine.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}